Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-00734200 · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 30 mg QD | EXPERIMENTAL | - |
| 20 mg QD | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| PF-00734200 10 mg QD | EXPERIMENTAL | - |
| PF-00734200 20 mg QD | EXPERIMENTAL | - |
| PF-00734200 5 mg QD | EXPERIMENTAL | - |
| PF-00734200 2 mg QD | EXPERIMENTAL | - |
| PF-00734200 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-00734200 30 mg QD | DRUG | 30 mg QD |
| PF-00734200 20 mg QD | DRUG | 20 mg QD |
| Placebo | DRUG | Placebo |
| PF-00734200 10 mg QD | DRUG | 10 mg QD |
| PF-00734200 5 mg QD | DRUG | 5 mg QD |
| PF-00734200 2 mg QD | DRUG | 2 mg QD |
| PF-00734200 | DRUG | The drug is administered as a single dose of four 5-mg tablets |
Inclusion Criteria: Men or women between 18-80 years of age with poorly controlled Type 2 diabetes Exclusion Criteria: Type 1 or secondary forms of diabetes Currently using insulin
PF-00734200 is an investigational small molecule developed by Pfizer for metabolic conditions. It has been studied in Phase 2 clinical trials for type 2 diabetes mellitus and in a Phase 1 trial for chronic renal insufficiency. It is not approved and remains in clinical development.
PF-00734200 has been evaluated as a treatment for type 2 diabetes mellitus. Two completed Phase 2 trials studied it in adults with the condition, including one in patients already treated with metformin. It is investigational and has not been approved for any use.
PF-00734200 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the clinical trials of the drug in type 2 diabetes and chronic renal insufficiency.
PF-00734200 is in Phase 2 development. Two Phase 2 trials and one Phase 1 trial have been completed, and no trials are currently active. The drug is investigational and has not received FDA approval.
PF-00734200 has been studied in completed trials including NCT00618007, a Phase 2 trial in type 2 diabetes with 289 participants, NCT00473525, a 12-week Phase 2 trial in type 2 diabetes patients on metformin with 303 participants, and NCT00596518, a Phase 1 trial in chronic renal insufficiency with 30 participants.